application) The main goal of this application is to provide clinical and basic biomedical research training to urologists and Ph.D. scientists that are interested in genitourinary (GU) diseases. The ongoing need for training academic urologists and Ph.D. scientists derives from the current inadequate understanding of the GU diseases. The training of highly qualified urologists and Ph.D. scientists to pursue contemporary research relevant to diseases of the GU system is an investment that is essential to the nation's current and future health care needs. Our training program will develop scientists who can meet this medical challenge. We are fortunate to have 24 senior level investigators that are doing research on GU diseases. All these investigators have research funding from NIH and other funding agencies. These investigators have outstanding track records of training urologists and Ph.D. scientists for many years and most trainees have gone onto careers in academic medicine and many are currently funded by NIH and other granting agencies. This training program is a comprehensive multidisciplinary program in which both basic science and translational research will be conducted and both clinical and basic biomedical scientists will be benefited. Under this program trainees from underrepresented racial/ethnic group will be accommodated. Training opportunities in basic biomedical science, clinical science, epidemiology, biostatistics, recombinant DNA technology and cell biology will be provided with the goal of producing well-rounded interdisciplinary scientists. Specific mentoring by coordinated teams of clinician-investigators and basic scientists in specific GU research areas ensures comprehensive multidisciplinary research training. Under this program, 3 positions will be for Ph.D. post-doctoral fellows and two for M.D. fellows (these positions are based on the number of investigators and funded projects in this program). The first year of training will consist of course work in basic sciences and research ethics plus basic research laboratory techniques, or epidemiology and clinical research methods. In the remainder of first year and in second and third years, the trainees will work under the mentorship of faculty members in one of the research areas described in the proposal. Progress in the program will be evaluated through: (a) close individual supervision in the laboratory, (b) attendance of weekly research conferences and journal clubs, (c) participation at program-wide conferences and courses. UCSF provides a rich scientific environment through series of seminars, visiting professors, and conferences that create stimulating exchanges among trainees and mentors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Institutional National Research Service Award (T32)
Project #
5T32DK007790-04
Application #
6659713
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Moen, Laura K
Project Start
2000-09-15
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
4
Fiscal Year
2003
Total Cost
$26,523
Indirect Cost
Name
University of California San Francisco
Department
Urology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Ching, Saunders T; Cunha, Gerald R; Baskin, Laurence S et al. (2014) Coordinated activity of Spry1 and Spry2 is required for normal development of the external genitalia. Dev Biol 386:1-11
Arora, Sumit; Saini, Sharanjot; Fukuhara, Shinichiro et al. (2013) MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PLoS One 8:e78023
Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro et al. (2013) Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS One 8:e58929
Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro et al. (2013) Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One 8:e70372
Majid, Shahana; Dar, Altaf A; Saini, Sharanjot et al. (2013) miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res 19:73-84
Majid, Shahana; Dar, Altaf A; Saini, Sharanjot et al. (2012) miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res 72:6435-46
Yamamura, Soichiro; Saini, Sharanjot; Majid, Shahana et al. (2012) MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 33:294-300
Yamamura, Soichiro; Saini, Sharanjot; Majid, Shahana et al. (2012) MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 7:e29722
Chiyomaru, Takeshi; Yamamura, Soichiro; Zaman, Mohd Saif et al. (2012) Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151. PLoS One 7:e43812
Hirata, Hiroshi; Hinoda, Yuji; Ueno, Koji et al. (2012) MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33:41-8

Showing the most recent 10 out of 76 publications